Vir

View All

recent-pharma-biotech-news-updates-gilead-vir-teladoc-tessera-dexcom-verve
Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate

Gilead and Vir Biotechnology Establish Clinical Collaboration  Gilead Sciences, Inc. and Vir Biotechnology, Inc. announced that the companies have entered into a clinical collaboration to assess novel therapeutic combination strategies to develop a functional remedy for chronic hepatitis B virus (HBV). T...

Find More

pharma news
Vir’s drug shows results; Abbott launches coronavirus antibody lab test; Reprogrammed skin cells repair vision in mouse models; Moma Therapeutics focuses for molecular machines

Vir's Hepatitis B drug shows positive results in phase 2 The hepatitis B drug of Vir Biotechnology has shown promising results. Its gene-silencing drug trim levels of the hepatitis B surface antigen in a small phase 2 study in patients who are already taking antiretroviral drugs. The drug, VIR-2218,...

Find More